MedTrace Logo

Sacituzumab govitEcan in THYroid Cancers

NCT06235216 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2024-11-01

No results posted yet for this study

Summary

SETHY is a prospective, multicohort, phase II, single-arm, non-randomized, non-blinded, investigator-initiated study of sacituzumab govitecan in patients with advanced or metastatic radioactive-iodine refractory differentiated thyroid carcinoma (DTC) or anaplastic thyroid carcinoma (ATC).

The main hypothesis is that treatment with sacituzumab govitecan, a anti-Trophoblast cell surface antigen 2 (TROP-2), could be an effective treatment option for patients with either differentiated and anaplastic thyroid neoplasms because TROP-2 is highly expressed at the membrane of DTC and ATC.

Conditions

  • Differentiated Thyroid Cancer
  • Anaplastic Thyroid Cancer

Interventions

DRUG

Sacituzumab govitecan

Dose of 10 mg/kg intravenously

Sponsors & Collaborators

  • MFAR

    collaborator OTHER

  • Gilead Sciences

    collaborator INDUSTRY

  • Grupo Espanol de Tumores Neuroendocrinos

    lead OTHER

Principal Investigators

  • Alejandro García-Alvarez, M.D.; Ph.D. · Hospital Universitario Vall d´Hebron

  • Jaume Capdevila, M.D.; Ph.D. · Hospital Universitario Vall d´Hebron

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-13
Primary Completion
2027-12-31
Completion
2027-12-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06235216 on ClinicalTrials.gov